West Pharma (WST) Tops Q1 EPS by 22c, provides guidance

West Pharma (NYSE: WST) reported Q1 EPS of $1.45, $0.22 better than the analyst estimate of $1.23. Revenue for the quarter came in at $698 million versus the consensus estimate of $684.94 million.

GUIDANCE:

West Pharma sees FY2025 EPS of $6.15-$6.35, versus the consensus of $7.02. West Pharma sees FY2025 revenue of $2.945-2.975 billion, versus the consensus of $3.093 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Hitachi Ltd. (HIT) Misses Q2 EPS by 7c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c